This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Sloan-Kettering Institute for Cancer Research. Active years: 2003-2008.
Company Filing History:
Years Active: 2003-2008
Title: John Pinto: Innovator in Cancer Research
Introduction
John Pinto is a notable inventor based in East Norwalk, Connecticut. He has made significant contributions to the field of cancer research, particularly in the development of therapies targeting prostate-specific membrane antigens. With a total of 2 patents, Pinto's work is instrumental in advancing medical science.
Latest Patents
Pinto's latest patents include innovative methods and compositions related to prostate-specific membrane antigens. One of his inventions provides a method of administering methotrexate triglutamate (MTXglu3), which inhibits the neurocarboxypeptidase activity of prostate-specific membrane antigen. This method aims to reduce the release of glutamate by N-acetylaspartylglutamic acid (NAAG) hydrolysis in subjects. Another patent focuses on an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention also includes a method for detecting prostate tumor cells in subjects and a pharmaceutical composition that enhances the susceptibility of prostate cells to cytotoxic chemotherapeutic agents.
Career Highlights
John Pinto is affiliated with the Sloan-Kettering Institute for Cancer Research, where he continues to work on groundbreaking research in oncology. His contributions have been vital in the quest for effective cancer treatments.
Collaborations
Pinto has collaborated with esteemed colleagues such as Ouathek Ouerfelli and Warren D W Heston. These partnerships have further enriched his research endeavors and have led to advancements in cancer therapies.
Conclusion
John Pinto's innovative work in cancer research, particularly regarding prostate-specific membrane antigens, showcases his dedication to improving therapeutic options for patients. His patents reflect a commitment to advancing medical science and enhancing treatment efficacy.